United States

Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

17 Feb 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Thu, Nov 3 2016

BRIEF-Achillion Q3 loss per share $0.15

* Achillion Pharmaceuticals Inc says recognized in q3 of 2015 revenue of $33.8 million under janssen agreement

BRIEF-Achillion announces data from phase 2 trial for combination treatment for Genotype 1 Treatment-Naïve HCV

* Announces 100 pct SVR12 In The 6-Week and 8-week cohorts in Janssen'S phase 2 trial evaluating the triple combination treatment regimen including odalasvir, al-335, and simeprevir for genotype 1 treatment-naïve hcv

BRIEF-Achillion, J&J post promising interim data on Hep C combination drug

* Announces 100% SVR Reported In Janssen'S Phase 2a Trial Evaluating Triple Combination Of Odalasvir, Al 335, and simeprevir for genotype 1 treatment-naive HCV

Select another date:

More From Around the Web